Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-303
2024-512915-33-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing XL092 + Tecentriq with Stivarga (2 arms). Primary endpoint: Overall survival. Planned start Dec 2022; status: authorised.
02
Drugs
zanzalintinibatezolizumabregorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-512915-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512915-33-00.